Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab
Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab
复制标题
DOI：
10.1016/j.jceh.2019.11.009
复制
发表时间：
2020-03-01
影响因子：
3
通讯作者：
Thuluvath, Paul J.
中科院分区：
文献类型：
--
作者：
Amjad, Waseem;Kotiah, Sandy;Thuluvath, Paul J.
在移植受者中使用免疫疗法被认为是禁忌症，因为移植物丢失的风险非常高。由于细胞毒性T淋巴细胞相关蛋白-4和程序性死亡1途径与移植耐受有关，因此移植物丢失是可以预期的。在这份病例报告中，我们描述了一名患有复发性播散性肝细胞癌的女性，她成功地接受了免疫检查点抑制剂nivolumab的治疗。
The use of immunotherapy in transplant recipients is considered a contraindication because of very high risks for graft loss. The graft loss is to be expected because cytotoxic T-lymphocyte-associated protein-4 and programmed death 1 pathways are implicated in graft tolerance. In this case report, we describe a woman with recurrent, disseminated hepatocellular carcinoma who was successfully treated with nivolumab, an immune checkpoint inhibitor.